Hepatogastroenterology 60 (126), 12891296
If this technology matures, it could bridge the gap between the modest effects of current probiotics and the potent effects of pharmaceutical GLP-1 agonists
Results and discussion Worldwide, G6PD deficiency is frequently seen in African, Mediterranean, Middle East and far East nations and their lineages, with a frequency ranging from 5% to 40%Citation28
Jul 24 2025;26(15)doi:10.3390/ijms26157159 Wallace TC, Fulgoni VL, 3rd
Published today in Nature Health , the study covers over five years of public online posts from nearly 70,000 Reddit users discussing their personal experience taking the GLP-1 drugs semaglutide and tirzepatide
Staff is very friendly and accommodating